Loading
A phase 3 trial of Thyrotropin alfa in Thyroid cancer, run by Suzhou Zelgen Biopharmaceuticals Co.,Ltd, completed.
rhTSH for Radioactive Iodine Remnant Ablation in Participants With Differentiated Thyroid Cancer (DTC) is a phase 3 interventional study registered as NCT04964284 by Suzhou Zelgen Biopharmaceuticals Co.,Ltd, with 390 participants recorded, started 2021-10-06 and reaching its primary completion in 2026-01-31. Interventions recorded: rhTSH, Radioiodine (131I). Conditions recorded: Differentiated Thyroid Cancer.
Linked to the drug Thyrotropin alfa because the registry names it among its interventions and Thyroid cancer among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Thyrotropin alfa, Suzhou Zelgen Biopharmaceuticals, Thyroid cancer and the tag pipeline.
Shares Thyrotropin alfa, Thyroid cancer and the tag pipeline.
Shares Suzhou Zelgen Biopharmaceuticals and the tag pipeline.
Shares Suzhou Zelgen Biopharmaceuticals and the tag pipeline.
Shares Suzhou Zelgen Biopharmaceuticals and the tag pipeline.
Shares Suzhou Zelgen Biopharmaceuticals and the tag pipeline.
Shares Suzhou Zelgen Biopharmaceuticals and the tag pipeline.
Shares Suzhou Zelgen Biopharmaceuticals and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/